Mind Medicine (MindMed) (OTCMKTS:MMEDF) Stock Jumps 3.9% – Here’s Why

Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDF)’s share price traded up 3.9% on Friday. The company traded as high as $37.61 and last traded at $37.08. 1,282,373 shares changed hands during mid-day trading, a decline of 62% from the average daily volume of 3,376,665 shares. The stock had previously closed at $35.68.

Mind Medicine (MindMed) Stock Down 4.3%

The company’s fifty day simple moving average is $37.91 and its 200-day simple moving average is $29.32.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company developing treatments for brain health disorders. The company focuses on psychedelic-inspired medicines intended to address conditions with significant unmet medical needs, including anxiety and mood disorders.

MindMed’s lead program, MM-120, is a proprietary formulation of lysergide, commonly known as LSD, being studied for generalized anxiety disorder and other neuropsychiatric conditions. The company is also developing MM-402, an ibogaine-derived therapy candidate intended for potential use in substance use and other brain-related disorders.

Founded in 2019, MindMed conducts research and clinical development activities through collaborations with academic institutions, medical researchers and other industry partners.